Slingshot members are tracking this event:

CymaBay(CBAY) Halts Clinical Development of Seladelpar

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details
The decision to halt development of seladelpar was based on initial histological findings observed in the Phase 2b study of seladelpar in NASH. Planned, blinded histological assessments of the first tranche of liver biopsies in the trial revealed atypical histological findings, including histology characterized as an interface hepatitis presentation, with or without biliary injury. The company has initiated a series of investigative actions to better understand these findings.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 25, 2019
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Seladelpar, Non-alcoholic Steatohepatitis, Discontinuation